Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021
Caroline L Behr, Karen E. Joynt Maddox, Ellen Meara, Arnold M. Epstein, E. John Orav, Michael L. Barnett
Abstract
This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMonoclonal antibodyVirologyPopulationDiseaseAntibodyImmunologyInternal medicineInfectious disease (medical specialty)Environmental healthOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies